Call for Abstract
Scientific Program
5th International Conference on Central Nervous System Disorders & Therapeutics, will be organized around the theme “Accelerate the diagnosis, prevention & management of CNS disorders”
CNS 2019 is comprised of 17 tracks and 122 sessions designed to offer comprehensive sessions that address current issues in CNS 2019.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
Central Nervous System might be characterized as the framework which is comprised of the cerebrum and spinal cord. The CNS is helpless against different diseases. CNS can be harmed by the accompanying: Trauma, Infections, Degeneration, Structural deformities, Tumors, Bloodstream disturbance, Autoimmune disorders and so on.
Around 22 million patients experience the ill effects of different types of dementia, 66% of which are identified with Alzheimer's. The WHO gauges the quantity of individuals experiencing various sclerosis worldwide at 2.5 million. Concerning schizophrenia, 1percent of the total populace might be in danger.
- Track 1-1Addiction
- Track 1-2Cerebral edema
- Track 1-3Functional and structural disorders
- Track 1-4 Arnold–Chiari malformation
- Track 1-5 Arnold–Chiari malformation
- Track 1-6Bipolar Disorder
- Track 1-7 Neuromyelitis optica
- Track 1-8Hydrocephalus
- Track 1-9CNS Neoplasia
- Track 1-10Spinal meningitis
- Track 1-11Holoprosencephaly
- Track 1-12Holoprosencephaly
- Track 1-13CNS demyelinating disorders
- Track 1-14Development of Therapeutics for CNS Disorders
- Track 1-15Genetic determinants of brain reorganisation and learning
- Track 1-16
- Track 2-1 Eating disorders
- Track 2-2 Mood disorders
- Track 2-3Childhood and adolescent psychiatry
- Track 2-4Neuroanatomy and physiology
- Track 2-5Neuropsychiatric disturbances
- Track 2-6Psychosis
- Track 2-7Sleep disorders
- Track 3-1Cerebral Ischemia
- Track 3-2 Cerebral hemorrhage
- Track 3-3Cerebral embolism
- Track 3-4 Cerebral aneurysm
- Track 3-5Vascular malformation
- Track 3-6Risk factors for cerebrovascular diseases
- Track 3-7 Epidemiology of cerebrovascular diseases
- Track 3-8Technological advances in vascular surgery
- Track 4-1 Brain Disorders
- Track 4-2 Spinal Disorders
- Track 4-3Depression, Migraines and Headaches
- Track 4-4Attention Deficit Hyperactivity Disorder
- Track 4-5Multiple sclerosis
- Track 4-6Schizophrenia
- Track 4-7Parkinsonism and Movement Disorders
- Track 4-8Dementia (AD)
- Track 4-9Prion disease
- Track 4-10 Werdnig-Hoffmann Disease
- Track 5-1 Neurocognitive
- Track 5-2Cognitive Genomics & behavioural genetics
- Track 5-3Evolution and Social Cognition
- Track 5-4Methods of cognitive neurosciencce
- Track 5-5Neurobehavioral and Cognitive Disorders
- Track 6-1 Brain and Spinal surgery
- Track 6-2Anatomical and functional Neural circuits
- Track 6-3Current Neurosurgery methods
- Track 6-4Neuropathological disorders
- Track 6-5Tumour and metastatis
- Track 7-1Spinal Column Anatomy
- Track 7-2Levels of Injury
- Track 7-3Spinal Stenosis
- Track 7-4Sciatica
- Track 7-5coliosis Spine
- Track 7-6Spinal stroke
- Track 7-7Spine tumors
- Track 7-8Spinal Disorders Test
- Track 7-9Therapeutic approaches for spinal disorders
- Track 8-1 CNS Inflammation
- Track 8-2 Neuroimmunomodulation
- Track 8-3CNS–immune system interactions
- Track 8-4Immunochemical cerebrospinal fluid
- Track 8-5Inflammatory and Autoimmune Disorders
- Track 8-6Stem Cells in Neuroimmunology
- Track 9-1 Dopamine
- Track 9-2Advances in astrocyte-neuron interactions in health and disease
- Track 9-3Drug interaction in various stages in neurotransmitters
- Track 9-4Neuropeptides
- Track 9-5Serotonin
- Track 10-1 Mechanisms of neurogenesis
- Track 10-2Adult neurogenesis
- Track 10-3Neural Development
- Track 10-4Neurogenesis
- Track 10-5Neuronal Migration
- Track 10-6Neurons and Neuronal system
- Track 10-7Neuroplasticity
- Track 11-1 Neurotoxicity and Neuroprotection
- Track 11-2Central Nervous System Cancers
- Track 11-3Clinical problems in neurooncology
- Track 11-4Metastatic tumors
- Track 11-5Neurobiology
- Track 11-6Neuroimaging and novel technologies
- Track 11-7Neuropathology
- Track 12-1 Clinical development in MS, PD and AD
- Track 12-2Biomarkers implication in clinical trials
- Track 12-3Current challenges in translational CNS research
- Track 12-4Improvment of clinical trial development
- Track 12-5 Facilitating and establishing industry and academic partnering
- Track 12-6Clinical trial safety and evaluation
- Track 12-7 New approaches for the design of clinical trials
- Track 12-8Case reports related to CNS disorders and Neurology
- Track 12-9 Remedies for CNS & Neurological Disorders
- Track 13-1Biomarker Challenges in Rare Diseases
- Track 13-2Cerebrospinal fluid biomarkers
- Track 13-3CNS drug development using biomarkers
- Track 13-4Neuroimaging enrichment biomarkers for CNS diseases
- Track 13-5Technology case studies for CNS
- Track 14-1 Genetic determinants of brain reorganisation and learning
- Track 14-2Advances in neurorehabilitation fundamentals
- Track 14-3Modular motor therapies
- Track 14-4Neurologic music therapy in non-motor problems Related Conference of Neuro rehabilitation and Technological Developments in neurorehabilitation
- Track 15-1Neuro Immune Pharmacology
- Track 15-2Psychopharmacology
- Track 15-3Antipsychotic drugs/ Neuroleptics
- Track 15-4Physical Therapy
- Track 15-5Surgical aggression and Anesthesia
- Track 15-6Clinical Pharmacists
- Track 15-7Neuroethics
- Track 15-8 Future Aspects of Neuropharmacology
- Track 16-1 Neuro Engineering
- Track 16-2Clinical neurophysiology
- Track 16-3Cognitive Neuroscience
- Track 16-4Computational Neuroscience
- Track 16-5Neurological Nursing
- Track 17-1Centrally acting analgesics
- Track 17-2Blood brain barrier (BBB)
- Track 17-3Metabolism mediated drug-drug interactions
- Track 17-4Enzyme kinetics
- Track 17-5Role of drug metabolism in drug development
- Track 17-6Neurological Drug Targets